Regenerative Biologics
for Dermatological
Conditions

Psoriasis is driven by the IL-23/Th17 immune axis — IL-23 from dendritic cells drives Th17 differentiation, which secretes IL-17A and IL-22 that drive keratinocyte hyperproliferation, epidermal thickening, and the neutrophil-rich Munro’s microabscess of the psoriatic plaque. Conventional systemic biologics (secukinumab, ixekizumab, guselkumab) target these cytokines with high efficacy but significant immunosuppressive burden and cost.

MSC immunomodulation provides an alternative immunological approach: IDO-mediated T-cell suppression, PGE2-driven Treg expansion, and IL-10 secretion suppress the Th17 axis through upstream cellular regulation rather than cytokine neutralization. Phase I/II series show PASI 50 rates of 60% and PASI 75 rates of 33% without systemic immunosuppression — a meaningful clinical signal that supports Phase II RCT development for moderate plaque psoriasis that has failed topical therapy but where systemic biologic cost or immunosuppression risk is a barrier.

Vitiligo — affecting approximately 1–2% of the global population — is an autoimmune condition in which CD8+ cytotoxic T cells destroy melanocytes through IFN-γ/CXCL9/CXCL10-mediated recruitment and cytotoxic killing. The condition carries significant psychosocial impact and has limited conventional treatment options — narrowband UVB, JAK inhibitors (ritlecitinib, ruxolitinib), and surgical repigmentation for stable disease.

PRP’s immunomodulatory TGF-β1 content promotes Treg expansion that suppresses the autoreactive CD8+ T-cell attack on melanocytes, while PDGF-BB and SCF in PRP provide chemotactic signals for melanocyte migration from the follicular melanocyte reservoir into the depigmented epidermis. The perifollicular repigmentation pattern observed in clinical series directly confirms this follicular recruitment mechanism. WJ-MSC intradermal injection adds deeper immunosuppressive depth (HLA-G, IDO, PGE2) that may be necessary in rapidly progressive or treatment-refractory vitiligo.

Chronic leg ulcers — managed extensively in dermatology practice, particularly by wound care-focused dermatologists — represent the overlap between the wound healing condition page and the dermatological condition page. The biological failures of chronic wound stall (MMP overactivity, M1 macrophage lock, vascular insufficiency, cellular senescence) are addressed through the same mechanisms discussed in the wound healing section.

In the dermatology practice context, lyophilized amniotic membrane is the primary biologic — applied weekly over compression dressings for VLU, and applied biweekly with offloading for DFU. The 67.6% closure rate in the Driver 2018 series for compression-refractory VLU and the multiple RCTs in DFU are the same foundational evidence cited in both pages. The practice setting difference is in compression management, patient population, and the dermatologist’s role in the care coordination — not in the biologic mechanism or product selection.

Hypertrophic scars and keloids represent a failure of the normal wound healing resolution phase. Conventional treatment — intralesional corticosteroid, ablative laser, pressure therapy, silicone sheeting — provides partial symptom relief but does not address the primary pathological driver: TGF-β1-mediated fibroblast-to-myofibroblast transdifferentiation and the sustained collagen deposition that defines these conditions.

Amniotic membrane’s TSG-6 and TGF-β3 profile directly suppresses myofibroblast persistence and promotes scarless collagen remodeling — the only biologic on this platform with this specific anti-fibrotic mechanism. Intralesional PRP at appropriate concentrations (paradoxically anti-fibrotic through MMP upregulation and normalized matrix remodeling) has also been evaluated. The strongest evidence is for prevention (amniotic membrane at surgical closure) rather than established keloid treatment, where the fibrotic process is already entrenched and harder to reverse.

Post-inflammatory hyperpigmentation (PIH) is among the most prevalent and treatment-resistant conditions in darker skin types — affecting patients after acne, eczema, procedures, and cutaneous injuries. Conventional management relies on tyrosinase inhibitors (hydroquinone, kojic acid, azelaic acid) that reduce melanin synthesis but do not address the upstream melanocyte-stimulating inflammatory signaling driving PIH.

Biologic approaches target PIH at two distinct levels: (1) prevention — PRP applied post-ablative procedure reduces re-epithelialization time and the duration of post-procedure inflammation, significantly reducing PIH incidence; (2) treatment — MSC-derived exosome miR-132 and miR-219 directly downregulate MITF and tyrosinase expression, suppressing melanocyte activity at the transcriptional level rather than merely at the enzyme level. Combination protocols (exosomes delivered post-microneedling) provide both epigenetic melanocyte suppression and growth factor-driven skin quality improvement simultaneously.

Radiation skin damage — both acute radiation dermatitis during treatment and late radiation effects (atrophy, fibrosis, telangiectasia, hypopigmentation) following completed radiotherapy — represents one of the most biologically severe and treatment-resistant conditions in dermatological practice. Late radiation effects result from radiation-induced fibrosis, vascular obliteration, and depletion of the skin’s stem cell reserve — three concurrent mechanisms that converge to produce the characteristic hard, atrophic, poorly healing radiated skin.

SVF injection is the most impactful biologic for late radiation effects — directly addressing all three pathological mechanisms through MSC anti-fibrotic paracrine (TSG-6, TGF-β3), pericyte-mediated vascular reconstruction (VEGF, Ang-1), and stem cell repletion of the depleted dermal progenitor reserve. The Rigotti 2012 study (48% elasticity improvement, significant fibrosis reduction on histology) represents one of the most dramatic biologic outcomes in dermatology for a condition where no other effective treatment exists. Acute radiation dermatitis is managed with amniotic membrane coverage (anti-inflammatory, epithelialization support) and PRP.

Mohs micrographic surgery generates the highest volume of complex cutaneous defects in dermatological practice — with approximately 1 million procedures performed annually in the US. While most Mohs defects are repaired primarily or with local flaps, a significant proportion undergo secondary intention healing, particularly in cosmetically sensitive locations where flap or graft repair produces inferior aesthetic outcomes.

Amniotic membrane as a biological wound covering for granulating Mohs defects provides a biologically active scaffold that guides organized re-epithelialization, reduces hypertrophic scar formation, and maintains a moist, anti-inflammatory wound environment. Lyophilized ADM for larger full-thickness defects provides the structural dermal depth that amniotic membrane alone cannot supply. In the post-Mohs wound care context, the ambient storage format of lyophilized products eliminates the cold-chain coordination that would otherwise make biologic wound care impractical in a dermatology office setting.